The effective anti-tumor activity through birinapant, TRAIL, and TRAILR2/DR5 antibody triple combination observed in this study is consistent with observations from the antibody effect against TRAILR2/DR5 in other cancer types. This evidence concerns the gene TNFSF10 and cancer.